Opus Genetics Announces FDA Clearance of IND Application for OPGx-RDH12 Gene Therapy for Inherited Childhood Blindness
The FDA cleared Opus Genetics' IND application for OPGx-RDH12, an AAV-based gene therapy for RDH12-associated Leber congenital amaurosis, a rare inherited retinal disease causing childhood blindness. The clearance lets the company advance its third gene therapy program into the clinic, with a Phase 1/2 trial planned to begin this quarter. The program is supported by the Global RDH12 Alliance, which committed up to $1.6 million in reimbursed development costs under a July 2025 venture-philanthropy collaboration.
Key figures
- Drug Name
- OPGx-RDH12
- Deal Value Usd
- 1600000
- Phase Of Trial
- Phase 1/2
- Pipeline programs
- 7
- Collaboration commitment
- up to $1.6 million from the Global RDH12 Alliance
- Global rd12 lca population
- 30900
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.